Trexquant Investment’s Aerie Pharmaceuticals AERI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-11,013
Closed -$176K 1613
2021
Q2
$176K Sell
11,013
-5,463
-33% -$93.7K 0.01% 942
2021
Q1
$294K Buy
16,476
+5,103
+45% +$88.1K 0.03% 765
2020
Q4
$154K Buy
+11,373
New +$137K 0.02% 935
2020
Q1
Sell
-16,626
Closed -$402K 1518
2019
Q4
$402K Buy
+16,626
New +$344K 0.02% 644
2019
Q3
Sell
-15,005
Closed -$443K 1190
2019
Q2
$443K Buy
+15,005
New +$578K 0.04% 499
2018
Q3
Sell
-5,401
Closed -$365K 1270
2018
Q2
$365K Sell
5,401
-24,115
-82% -$1.35M 0.03% 626
2018
Q1
$1.6M Buy
29,516
+25,422
+621% +$1.42M 0.11% 294
2017
Q4
$245K Buy
+4,094
New +$248K 0.03% 836
2017
Q3
Sell
-7,700
Closed -$405K 1102
2017
Q2
$405K Buy
+7,700
New +$359K 0.11% 334
2017
Q1
Sell
-10,566
Closed -$400K 1386
2016
Q4
$400K Buy
10,566
+3,821
+57% +$144K 0.06% 535
2016
Q3
$255K Buy
+6,745
New +$149K 0.06% 548
2015
Q4
Sell
-31,570
Closed -$560K 1342
2015
Q3
$560K Buy
+31,570
New +$572K 0.05% 679
2015
Q2
Sell
-20,100
Closed -$629K 1315
2015
Q1
$629K Buy
+20,100
New +$583K 0.06% 598

Other funds holding AERI

Trexquant Investment's AERI Position: Q3 2021 in Review

Trexquant Investment sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 11,013 shares — an estimated $176K sold.

Trexquant Investment first reported a position in AERI in Q1 2015 and held it in 13 quarters. The position peaked at $1.6M in Q1 2018. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Trexquant Investment reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Trexquant Investment sold 11,013 Aerie Pharmaceuticals shares in Q3 2021, an estimated $176K.
  • Trexquant Investment first reported a position in Aerie Pharmaceuticals in Q1 2015 and held it in 13 quarters.
  • Trexquant Investment's Aerie Pharmaceuticals position peaked at $1.6M in Q1 2018.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Trexquant Investment's 13F filing for Q3 2021, filed 12 Nov 2021.